Substitute Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Information Disclosure Statement

by Applicant

by Applicant

(Use several sheets if necessary)

(37 CFR \$1.96(b))

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No.
11926-015002

Application No.
09/963,333

Fill

Application No.
11926-015002

MADEMARK	U.S. Patent Documents						200
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
AC	AA	6,015,673	1/18/2000	Gonzalez et al.	435	6	0
,	AB	6,074,821	6/13/2000	Rozen et al.	435	6	
	AC	6,130,043	10/10/2000	Billing-Medel et al.	435	6	
	AD	6,218,120	4/17/2001	Rozen et al.	435	6	
	AE						
	AF						
	AG						
	AH						·
	AI						:
	AJ						
	AK						
	AL		·			,	
	AM						

Foreign Patent Documents or Published Foreign Patent Applications							-	
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	slation No
	AN	WO 95/33054	12/7/1995	WIPO				
	AO							
	AP							
	AQ							
	AR							

		Other Documents (include Author, Title, Date, and Place of Publication)						
	Examine	r Desig.						
	Initial	ID_	Document					
 		AS	Akar et al., "Effect of Metylenetetrahydrofolate Reductase 677 C-T, 1298 A-C, and 1317 T-C on Facotr V" Thrombosis Research 97:163-167, 2000.					
2 [AT	Engbersen et al., "Thermolabile 5,10-Methylenetetrahydrofolate Reductase as a Cause of Mild Hyperhomocysteinemia" Am. J. of Human Genet. 56:142-150, 1995.					
<u> </u>	AC	AU	Frosst et al., "A Candidate Genetic Risk Factor for Vascular Disease: a Common Mutation in Methylenetetrahydrofolate Reductase" Nature Genetics 10:111-113, 1995.					

Examiner Signature

rom Kr. Chakpalegrob

Date Considered

12/2/02

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Substitute Form PTO-1449 U.S. Department of Common (Modified) Patent and Trademark O			Attorney's Docket No. 11926-015002	Application No. 09/963,333					
	Disclosure Statement by Applicant O Use several sheets if necessary) (37 CFR §1.98(b))			Applicant Vincent P. Stanton, Jr.						
				Filing Date September 24, 2001	Group Art Unit 9					
13		£		September 24, 2001 1033						
1	Other Documents (include Author, Title, Date, and Place of Publication)									
	Exa min er Initial	Desig. ID		Document & 2						
) Je	Goyette et al., "Human Methylenetetrahydrofolate Reductase: Isolation of cDNA, M.									
<u>-</u> -5-	AW Goyette et al., "Gene Structure of Human and Mouse Methylenetetrahydrofolate Reductase (MTHFR)" Mammalian Genome 9:652-656, 1998.									
-6-	-	Goyette et al., "Seven Novel Mutations in the Methylenetetrahydrofolate Reductase Gene and Genotype/Phenotype Correlations in Severe Methylenetetrahydrofolate Reductase Deficiency" Am. J. Hum. Genet. 56:1052-1059, 1995.								
A	AY Goyette et al., GenBank Accession No U09806, Dec. 6, 1999.									
4		AZ -	Kaneda et al., "Structural and Functional Analysis of the Human Thymidylate Synthase Gene" J. of Biol. Chem. 265:20277-20284, 1990.							
9-		AAA ,	Kang et al., "Thermolabile Methylenetetrahydrofolate Reductase: An Inherited Risk Factor for Coronary Artery Disease" Amer. J. Human. Genet. 48:536-545, 1991.							
10		ABB	Van der Put et al., "A Second Common Mutation in the Methelenetetrahydrofolate Reductase Gene: An Additional Risk Factor for Neural-Tube Defects" Am. J. Hum. Genet. 62:1044-1051, 1998.							
#		ACC .	Van Ede et al., "Methotrexate in Rheumatoid Arthiritis: An Update with Focus on Mechanisms Involved in Toxicity" Seminars in Arthiritis and Rheumatism 27:277-292, 1998.							
12		ADD /	Viel et al., "Loss of Heterozygosity at the 5,10-Methylenetetrahydrofolate Reductase Locus in Human Ovarian Carcinomas" British J. of Cancer 75:1105-1110, 1987.							
13	-Ae	AEE	Weisberg et al., "A second Genetic Polymorphism in Methylenetetrahydrofolate Reductase (MTHFR) Associate with Decreased Enzyme Activity" Mol. Genet. And Metabolism 64:169-172, 1998.							

Examiner Signature

un kr. Chakroslash

Date Considered

12/2/02

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.